TU Darmstadt / ULB / TUbiblio

Investigation of Biological and Technical Components for the Development of a 3D-Bioprinting Process for Vascularized Organs-on-a-Chip

Moritz-Fritschen, Anna (2024)
Investigation of Biological and Technical Components for the Development of a 3D-Bioprinting Process for Vascularized Organs-on-a-Chip.
Technische Universität Darmstadt
doi: 10.26083/tuprints-00027749
Dissertation, Erstveröffentlichung, Verlagsversion

Kurzbeschreibung (Abstract)

In today’s pharmaceutical research, conventional cell culture and animal testing are used to quantify the efficacy and safety of new pharmaceutical substances and drugs. The popularity of two-dimensional cell culture systems is based on their low costs in production and maintenance, high scalability, well-established testing and automated analysis methods. Despite these advantages, these methods often misjudge substances, resulting in late failures later on in human studies due to undetected side effects or reduced efficacy. In order to prevent these costly late failures, it is necessary to develop tissue models that more accurately and reliably represent human tissues in research. Such models require the targeted placement of multiple cell types in a matrix material that is similar to the human body, which can best be realized using high-resolution additive manufacturing such as microvalve-based 3D-bioprinting. To ensure nutrient supply and to mimic both the native nutrient and drug uptake, the integration of a blood vessel network into the tissue model is essential. The perfusion of these vascular networks can most reliably be realized on a microfluidic chip, which regulates liquid flow and drug administration. When tissue models are cultured under perfusion on such a microfluidic chip, they are called Organs-on-a-Chip. Despite the advantages of Organs-on-a-Chip over two-dimensional cell cultures, their use in pharmaceutical research remains limited as aspects such as their scaled-up fabrication and automatization in handling remain challenging. This work addresses the mentioned research aspects required for the automated fabrication of vascularized Organs-on-a-Chip for a translation of these models into preclinical pharmaceutical research. It focuses on the fabrication of a three-dimensional, vascularized and multicellular liver carcinoma Organ-on-a-Chip model via microvalve-based 3D-bioprinting. The objective is to determine if 3D-bioprinting can enhance automation in the fabrication of Organs-on-a-Chip and add a higher level of complexity as well as biomimetic vascular structures. In the first step, approaches to vascularization in Organs-on-a-Chip presented in the literature are reviewed, classified according to their degree of biomimicry and assessed for their suitability regarding the planned multi-cellular Organ-on-a-Chip. Based on this analysis, an approach compatible with the available bioprinting system and suitable for the envisioned tissue model is selected and employed in this work. Since the development of complex tissue models often requires multiple iterative steps concerning the microfluidic chip, conventional 3D-printing could enhance and accelerate the prototyping of these chips. Possible adaptations to the print process and a material selection of a conventional 3D-printer required to obtain transparent and cytocompatible components are therefore studied. This adapted process is then tested to examine if the print resolution as well as the general print process is capable of prototyping various microfluidic chip designs required for the tissue model and bioprint process. Next, a matrix material has to be selected that contains the liver carcinoma cells and that can be placed by the bioprinter with high precision and in small volumes. For this purpose, different hydrogel combinations are studied to identify a material that can retain and stimulate cell viability and growth without compromising the print resolution within the microfluidic chip. In the final step, the bioprinter is combined with a robotic handling unit to replace manual handling in the assembly of the Organ-on-a-Chip. This process is tested and assessed on the multi-cellular and vascularized liver carcinoma Organ-on-a-Chip. The resulting model is evaluated by the print resolution, the morphology of the vascular network and the proliferation of the liver carcinoma cells over a culture time of 14 days.

Typ des Eintrags: Dissertation
Erschienen: 2024
Autor(en): Moritz-Fritschen, Anna
Art des Eintrags: Erstveröffentlichung
Titel: Investigation of Biological and Technical Components for the Development of a 3D-Bioprinting Process for Vascularized Organs-on-a-Chip
Sprache: Englisch
Referenten: Blaeser, Prof. Dr. Andreas ; Stark, Prof. Dr. Robert
Publikationsjahr: 22 August 2024
Ort: Darmstadt
Kollation: xxii, 88 Seiten
Datum der mündlichen Prüfung: 17 Juli 2024
DOI: 10.26083/tuprints-00027749
URL / URN: https://tuprints.ulb.tu-darmstadt.de/27749
Kurzbeschreibung (Abstract):

In today’s pharmaceutical research, conventional cell culture and animal testing are used to quantify the efficacy and safety of new pharmaceutical substances and drugs. The popularity of two-dimensional cell culture systems is based on their low costs in production and maintenance, high scalability, well-established testing and automated analysis methods. Despite these advantages, these methods often misjudge substances, resulting in late failures later on in human studies due to undetected side effects or reduced efficacy. In order to prevent these costly late failures, it is necessary to develop tissue models that more accurately and reliably represent human tissues in research. Such models require the targeted placement of multiple cell types in a matrix material that is similar to the human body, which can best be realized using high-resolution additive manufacturing such as microvalve-based 3D-bioprinting. To ensure nutrient supply and to mimic both the native nutrient and drug uptake, the integration of a blood vessel network into the tissue model is essential. The perfusion of these vascular networks can most reliably be realized on a microfluidic chip, which regulates liquid flow and drug administration. When tissue models are cultured under perfusion on such a microfluidic chip, they are called Organs-on-a-Chip. Despite the advantages of Organs-on-a-Chip over two-dimensional cell cultures, their use in pharmaceutical research remains limited as aspects such as their scaled-up fabrication and automatization in handling remain challenging. This work addresses the mentioned research aspects required for the automated fabrication of vascularized Organs-on-a-Chip for a translation of these models into preclinical pharmaceutical research. It focuses on the fabrication of a three-dimensional, vascularized and multicellular liver carcinoma Organ-on-a-Chip model via microvalve-based 3D-bioprinting. The objective is to determine if 3D-bioprinting can enhance automation in the fabrication of Organs-on-a-Chip and add a higher level of complexity as well as biomimetic vascular structures. In the first step, approaches to vascularization in Organs-on-a-Chip presented in the literature are reviewed, classified according to their degree of biomimicry and assessed for their suitability regarding the planned multi-cellular Organ-on-a-Chip. Based on this analysis, an approach compatible with the available bioprinting system and suitable for the envisioned tissue model is selected and employed in this work. Since the development of complex tissue models often requires multiple iterative steps concerning the microfluidic chip, conventional 3D-printing could enhance and accelerate the prototyping of these chips. Possible adaptations to the print process and a material selection of a conventional 3D-printer required to obtain transparent and cytocompatible components are therefore studied. This adapted process is then tested to examine if the print resolution as well as the general print process is capable of prototyping various microfluidic chip designs required for the tissue model and bioprint process. Next, a matrix material has to be selected that contains the liver carcinoma cells and that can be placed by the bioprinter with high precision and in small volumes. For this purpose, different hydrogel combinations are studied to identify a material that can retain and stimulate cell viability and growth without compromising the print resolution within the microfluidic chip. In the final step, the bioprinter is combined with a robotic handling unit to replace manual handling in the assembly of the Organ-on-a-Chip. This process is tested and assessed on the multi-cellular and vascularized liver carcinoma Organ-on-a-Chip. The resulting model is evaluated by the print resolution, the morphology of the vascular network and the proliferation of the liver carcinoma cells over a culture time of 14 days.

Alternatives oder übersetztes Abstract:
Alternatives AbstractSprache

Aktuell dienen Zellkulturen und Tierversuche in der pharmazeutischen Forschung der Bewertung von Wirksamkeit und Sicherheit neuer Substanzen. Dabei beruht die Beliebtheit zweidimensionaler Zellkultursysteme auf ihrer kostengünstigen Herstellung und Wartung, der Skalierbarkeit und den bereits etablierten Analysemethoden. Trotz ihrer Vorteile führen diese Systeme oft zur Fehleinschätzung von Substanzen, die in späteren Studien an Menschen aufgrund von unerkannten Nebenwirkungen oder verminderter Wirksamkeit zu Fehlschlägen führen. Um kostspielige Misserfolge zu vermeiden, sind deutlich genauere und zuverlässigere Gewebemodelle notwendig. Solche Modelle erfordern die gezielte Platzierung verschiedener Zelltypen in einem Matrixmaterial, das der extrazellulären Matrix des menschlichen Körpers ähnelt. Dies kann am effektivsten durch hochauflösende 3D-Biodrucker umgesetzt werden. Um eine angemessene Nährstoffversorgung und die Nachahmung der nativen Nährstoff- sowie Medikamentenaufnahme zu imitieren, ist die Integration eines Blutgefäßnetzes in das Gewebemodell entscheidend. Die Perfusion dieser Gefäße lässt sich am besten mittels eines mikrofluidischen Chips realisieren, der den Flüssigkeitsfluss und die Medikamentenzufuhr reguliert. Solche perfundierten Gewebemodelle auf einem Mikrofluidikchip werden als Organs-on-a-Chip bezeichnet. Obwohl Organs-on-a-Chip gegenüber zweidimensionalen Zellkulturen Vorteile bieten, werden sie in der pharmazeutischen Forschung nur begrenzt eingesetzt, da Herausforderungen wie die Skalierbarkeit und die Automatisierung der Herstellung und Handhabung bestehen bleiben. Diese Arbeit befasst sich daher mit den Forschungsaspekten, die für die automatisierte Herstellung vaskularisierter Organs-on-a-Chip notwendig sind und ihre Anwendung in der präklinischen Arzneimittelforschung ermöglichen. Sie konzentriert sich auf die Herstellung eines dreidimensionalen, vaskularisierten und multizellulären Leberkarzinom-on-a-Chip mittels mikroventilbasiertem 3D-Biodruck. Ziel ist es festzustellen, ob der 3D-Biodruck die Herstellung von Organs-on-a-Chip automatisieren und ein höheres Maß an Komplexität sowie biomimetische Gefäßstrukturen hinzufügen kann. Zuerst werden in der Literatur vorgestellte Ansätze zur Vaskularisierung in Organs-on-a-Chip gesichtet, nach ihrem Grad der Biomimetik klassifiziert und ihre Eignung für das geplante Modell bewertet. Anhand dieser Analyse wird ein geeigneter und mit dem verfügbaren Biodrucker kompatibler Ansatz ausgewählt und in der Arbeit angewendet. Die Entwicklung komplexer Gewebemodelle erfordert oft mehrere Iterationen im Zusammenhang mit dem Design des eingesetzten Mikrofluidikchips, welche durch konventionellen 3D-Druck verbessert und beschleunigt werden könnten. Daher werden mögliche Anpassungen des Druckverfahrens und der Materialauswahl eines konventionellen 3D-Druckers untersucht, die nötig sind, um transparente und zytokompatible Bauteile zu erhalten. Dieser angepasste Prozess wird daraufhin hinsichtlich Druckauflösung und allgemeinem Druckprozess auf seine Eignung für die Prototypenherstellung untersucht. Als nächstes erfolgt die Auswahl eines Matrixmaterials für die Leberkrebszellen, das präzise und mit hoher Auflösung vom Biodrucker platziert werden kann. Verschiedene Hydrogel-Kombinationen werden untersucht, um ein Material zu identifizieren, welches die Vitalität und Proliferation der Zellen bewahrt ohne die Druckauflösung zu beeinträchtigen. Schließlich wird der Biodrucker mit einer Robotereinheit kombiniert, um die manuelle Handhabung bei der Herstellung des Organ-on-a-Chip zu automatisieren. Dieses Verfahren wird an einem multizellulären, vaskularisierten Leberkarzinom-on-a-Chip getestet und bewertet. Das resultierende Modell wird anhand der Druckauflösung, der Morphologie des Gefäßnetzes und der Proliferation der Leberkarzinomzellen über 14 Tage beurteilt.

Deutsch
Status: Verlagsversion
URN: urn:nbn:de:tuda-tuprints-277498
Sachgruppe der Dewey Dezimalklassifikatin (DDC): 500 Naturwissenschaften und Mathematik > 570 Biowissenschaften, Biologie
600 Technik, Medizin, angewandte Wissenschaften > 620 Ingenieurwissenschaften und Maschinenbau
Fachbereich(e)/-gebiet(e): 16 Fachbereich Maschinenbau
16 Fachbereich Maschinenbau > Institut für Druckmaschinen und Druckverfahren (IDD)
16 Fachbereich Maschinenbau > Institut für Druckmaschinen und Druckverfahren (IDD) > Biomedizinische Drucktechnologie (BMT)
Hinterlegungsdatum: 22 Aug 2024 12:47
Letzte Änderung: 26 Aug 2024 06:16
PPN:
Referenten: Blaeser, Prof. Dr. Andreas ; Stark, Prof. Dr. Robert
Datum der mündlichen Prüfung / Verteidigung / mdl. Prüfung: 17 Juli 2024
Export:
Suche nach Titel in: TUfind oder in Google
Frage zum Eintrag Frage zum Eintrag

Optionen (nur für Redakteure)
Redaktionelle Details anzeigen Redaktionelle Details anzeigen